Literature DB >> 23891436

MRI and (1)H MRS evaluation for the serial bile duct changes in hamsters after infection with Opisthorchis viverrini.

Petcharakorn Hanpanich1, Somchai Pinlaor, Lakhanawan Charoensuk, Puangrat Yongvanit, Chunpen Thomas, Suchart Kothan, Eimorn Mairiang.   

Abstract

A 3T MR scanner was used to investigate the relationship between the alteration of bile duct lesions and the hepatic metabolic changes in hamsters infected with Opisthorchis viverrini by using 3T MRI and (1)H MR spectroscopy. Animals were divided into control and infected groups. Five normal hamsters were used as control; fifty-five hamsters were infected with O. viverrini to induce bile duct lesions and hepatic metabolic changes. T2-weighted image sequence in three orthogonal planes were conducted by MRI scans. Single-voxel (1)H MRS was performed to obtain the relative choline-to-lipid ratios. The livers and bile ducts were excised for the histologic examination. The progression of bile duct changes by histology and metabolic changes in O. viverrini infected hamsters were co-investigated. In the O. viverrini-infected group, the T2-weighted images revealed the time-dependent intra- and extra-hepatic duct dilatations in the liver. The mean (±SD) choline-to-lipid ratios were 0.11±0.035 in the control group, whereas the ratio in the infected group increased significantly with the progression of time. Histologic grading of hepatic inflammation and fibrosis were correlated well with the MRI grading (Spearman rank correlation test; r=0.746 and p<0.001). The control group showed no dilatation of the bile ducts and showed normal liver patterns. Noninvasive technique, MRI and (1)H MRS can demonstrated and applied to evaluate not only the inflammation-related fibrosis in the small bile ducts but also the metabolic changes in the liver induced by O. viverrini infection. A significant increase in the choline-to-lipids ratios were observed in parallel with the time-course of infection. O. viverrini infected in human is detected by stool examination. Hepatobiliary morbidity is detected and followed up by ultrasonography. MRI and MRS can be used in conjunction with ultrasonography for evaluation of progression of the disease.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; MR imaging; Opisthorchis viverrini; Periductal fibrosis

Mesh:

Substances:

Year:  2013        PMID: 23891436     DOI: 10.1016/j.mri.2013.05.008

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  4 in total

1.  Magnetic Resonance Imaging of Reptiles, Rodents, and Lagomorphs for Clinical Diagnosis and Animal Research.

Authors:  Joanna Głodek; Zbigniew Adamiak; Adam Przeworski
Journal:  Comp Med       Date:  2016       Impact factor: 0.982

2.  Decreased risk of cholangiocarcinogenesis following repeated cycles of Opisthorchis viverrini infection-praziquantel treatment: Magnetic Resonance Imaging (MRI) and histopathological study in a hamster model.

Authors:  Petcharakorn Hanpanich; Thewarach Laha; Banchob Sripa; Eimorn Mairiang; Piya Sereerak; Songkaid Upontain; Prasarn Tangkawattana; Paul J Brindley; Sirikachorn Tangkawattana
Journal:  Parasitol Int       Date:  2016-04-30       Impact factor: 2.230

3.  Magnetic resonance imaging and spectroscopy for differential assessment of liver abnormalities induced by Opisthorchis felineus in an animal model.

Authors:  Alexandra G Pershina; Vladimir V Ivanov; Lina V Efimova; Oleg B Shevelev; Sergey V Vtorushin; Tatjana V Perevozchikova; Alexey E Sazonov; Ludmila M Ogorodova
Journal:  PLoS Negl Trop Dis       Date:  2017-07-14

4.  3-Aminopropylsilane-modified iron oxide nanoparticles for contrast-enhanced magnetic resonance imaging of liver lesions induced by Opisthorchis felineus.

Authors:  Alexander M Demin; Alexandra G Pershina; Vladimir V Ivanov; Kseniya V Nevskaya; Oleg B Shevelev; Artyom S Minin; Iliya V Byzov; Alexey E Sazonov; Victor P Krasnov; Ludmila M Ogorodova
Journal:  Int J Nanomedicine       Date:  2016-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.